What was known before

Despite advancements in the AMD treatment, there is still a large unmet need as GA continues to be a leading cause of central vision loss with no approved therapies.Evidence suggests a role of the complement pathway in AMD and GA and the potential for complement system components as therapeutic targets during GATHER1;avacincaptad pegol (ACP), an inhibitor of C5 cleavage, showed a significant reduction of GA growth (square root transformation) in both the 2 mg (27.4%, 